CU20120096A7 - Polipéptido de fusión contra tumor inducido por virus eb y mutante de colicina ia - Google Patents

Polipéptido de fusión contra tumor inducido por virus eb y mutante de colicina ia

Info

Publication number
CU20120096A7
CU20120096A7 CU2012000096A CU20120096A CU20120096A7 CU 20120096 A7 CU20120096 A7 CU 20120096A7 CU 2012000096 A CU2012000096 A CU 2012000096A CU 20120096 A CU20120096 A CU 20120096A CU 20120096 A7 CU20120096 A7 CU 20120096A7
Authority
CU
Cuba
Prior art keywords
mutant
colicina
polipeptide
provides
against virus
Prior art date
Application number
CU2012000096A
Other languages
English (en)
Other versions
CU23931B1 (es
Inventor
Xiaoqing Qiu
Original Assignee
Protein Design Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Lab Ltd filed Critical Protein Design Lab Ltd
Publication of CU20120096A7 publication Critical patent/CU20120096A7/es
Publication of CU23931B1 publication Critical patent/CU23931B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona un polipéptido de fusión contra tumor inducido por virus EB, que comprende un anticuerpo o un anticuerpo mimético contra el virus EB y una colicina que forma canales iónicos seleccionada de E1, Ia, Ib, A, B, N y sus mutantes. La presente invención también proporciona un mutante de colicina la, que comprende mutaciones de G11A, H22G, A26G, V31L y H40D. La presente invención también proporciona un gen, un vector, un método de preparación y el uso del polipéptido de fusión, y proporciona un gen y el uso del mutante.
CU2012000096A 2009-12-17 2012-06-12 Polipéptido de fusión contra tumor inducido por virus eb y mutante de colicina ia CU20120096A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009102428380A CN102101888B (zh) 2009-12-17 2009-12-17 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法
PCT/CN2010/070762 WO2011072501A1 (zh) 2009-12-17 2010-02-26 抗EB病毒诱发的肿瘤的融合多肽和大肠菌素Ia突变体

Publications (2)

Publication Number Publication Date
CU20120096A7 true CU20120096A7 (es) 2012-07-31
CU23931B1 CU23931B1 (es) 2013-06-28

Family

ID=44154977

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000096A CU20120096A7 (es) 2009-12-17 2012-06-12 Polipéptido de fusión contra tumor inducido por virus eb y mutante de colicina ia

Country Status (30)

Country Link
US (1) US8883161B2 (es)
EP (1) EP2514768B1 (es)
JP (1) JP5683603B2 (es)
KR (1) KR101464842B1 (es)
CN (1) CN102101888B (es)
AP (1) AP3535A (es)
AU (1) AU2010333588B2 (es)
BR (1) BR112012017350A2 (es)
CA (1) CA2784784C (es)
CL (1) CL2012001609A1 (es)
CO (1) CO6541633A2 (es)
CR (1) CR20120329A (es)
CU (1) CU20120096A7 (es)
DK (1) DK2514768T3 (es)
DO (1) DOP2012000164A (es)
EA (1) EA030638B1 (es)
ES (1) ES2634944T3 (es)
GE (1) GEP20156228B (es)
HU (1) HUE033298T2 (es)
IL (1) IL220296A (es)
MA (1) MA33921B1 (es)
MX (1) MX2012006952A (es)
NZ (1) NZ600729A (es)
PE (1) PE20121722A1 (es)
PH (1) PH12012501134A1 (es)
SG (1) SG181553A1 (es)
TN (1) TN2012000253A1 (es)
UA (1) UA104933C2 (es)
WO (1) WO2011072501A1 (es)
ZA (1) ZA201205217B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
DK2789632T3 (en) * 2011-12-08 2018-08-06 Protein Design Lab Ltd HOW TO UNKNOWN METHOD FOR PRODUCING ANTIBIOTICS AND PLATFORM SYSTEM BASED ON THESE
WO2016023491A1 (en) * 2014-08-12 2016-02-18 The University Of Hong Kong Biophosphonate compounds and gamma delta t cell-mediated therapy for treating epstein-barr virus-associated disorders
CN104604799B (zh) * 2015-02-05 2017-11-21 南华大学 一种鉴定eb病毒对淋巴瘤的诱发性的方法
CN113227790A (zh) * 2018-11-19 2021-08-06 拜尔阿斯特公司 用于多重结合实验的方法及试剂
CN111333724B (zh) * 2018-12-19 2022-03-15 中国人民解放军军事科学院军事医学研究院 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用
CN111848817B (zh) * 2020-07-28 2021-11-09 中国农业大学 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用
CN112125959B (zh) * 2020-10-10 2022-07-29 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用
CN113880914B (zh) * 2021-04-25 2023-11-21 内蒙古农业大学 一种抗肿瘤多肽及其衍生物
CN114369158B (zh) * 2021-09-28 2024-04-19 北京亦科信息菌素研究院有限公司 一种抗新冠病毒的信息菌素及其应用
CN113999304B (zh) * 2021-10-13 2023-10-24 北京市农林科学院 抗肠菌素单克隆抗体mAb4及其在肠菌素检测中的应用
CN119798448B (zh) * 2024-05-10 2025-11-07 成都一棵树未来医药科技有限公司 一种抗小细胞肺癌的信息菌素阵列及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164612C (zh) 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
CN1314806C (zh) * 2005-01-14 2007-05-09 四川大学 小型化抗eb病毒肿瘤多肽及其应用与制备方法
CN1274829C (zh) * 2004-12-10 2006-09-13 四川大学华西医院 抗eb病毒所致肿瘤多肽及其应用与制备方法
WO2007083175A1 (en) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Antiviral bifunctional molecules, methods of construction and methods of treating virus-induced cancer therewith
CN101643501B (zh) 2008-11-07 2012-06-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗生素及其核苷酸序列、制备方法与应用
CN101633699B (zh) * 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用

Also Published As

Publication number Publication date
CN102101888B (zh) 2013-03-20
HUE033298T2 (en) 2017-11-28
PH12012501134A1 (en) 2012-11-05
DOP2012000164A (es) 2012-12-31
EP2514768A1 (en) 2012-10-24
MA33921B1 (fr) 2013-01-02
IL220296A0 (en) 2012-07-31
IL220296A (en) 2017-07-31
NZ600729A (en) 2014-12-24
KR101464842B1 (ko) 2014-11-27
CN102101888A (zh) 2011-06-22
WO2011072501A1 (zh) 2011-06-23
US20130066051A1 (en) 2013-03-14
SG181553A1 (en) 2012-07-30
ZA201205217B (en) 2013-03-27
AP2012006327A0 (en) 2012-06-30
HK1159123A1 (en) 2012-07-27
GEP20156228B (en) 2015-01-26
AP3535A (en) 2016-01-13
AU2010333588A1 (en) 2012-06-21
CU23931B1 (es) 2013-06-28
EA030638B1 (ru) 2018-09-28
US8883161B2 (en) 2014-11-11
KR20120117826A (ko) 2012-10-24
DK2514768T3 (en) 2017-07-17
JP5683603B2 (ja) 2015-03-11
CO6541633A2 (es) 2012-10-16
CL2012001609A1 (es) 2012-12-07
AU2010333588B2 (en) 2013-05-02
CA2784784C (en) 2017-10-03
EP2514768A4 (en) 2013-12-04
CR20120329A (es) 2012-10-23
EP2514768B1 (en) 2017-04-05
CA2784784A1 (en) 2011-06-23
BR112012017350A2 (pt) 2018-07-24
EA201270655A1 (ru) 2012-12-28
PE20121722A1 (es) 2012-12-15
TN2012000253A1 (en) 2013-12-12
ES2634944T3 (es) 2017-09-29
JP2013514060A (ja) 2013-04-25
UA104933C2 (uk) 2014-03-25
MX2012006952A (es) 2012-10-03

Similar Documents

Publication Publication Date Title
CR20120329A (es) Polipéptido de fusión contra tumor inducido por virus eb y mutante de colicina ia
GT201200189A (es) Antagonistas de pcsk9
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
MY197846A (en) Optimized mini-dystrophin genes and expression cassettes and their use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2016015834A (es) Receptores quiméricos de antigeno que tienen como diana a cd-19.
EP4465050A3 (en) Anti-tau antibodies and methods of use
IN2014CN03463A (es)
NZ602119A (en) Peptide vaccines for cancers expressing tumor-associated antigens
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
PH12018500046A1 (en) Anti-mesothelin antibodies and immunoconjugates
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2018002106A (es) Vacunas terapeuticas contra el hpv18.
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
BR112012029912A2 (pt) vácinas de combinação de nanotransportadores sintéticos
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2012011829A (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
NZ731491A (en) Cd83 binding proteins and uses thereof
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
MX2017005310A (es) Metodos basados en proximidad para seleccion de parejas para ligadura.
EP3115377A4 (en) Mutant antibody of full human her2 antibody, coding gene and use thereof
MX2015009867A (es) Mutantes del factor x.

Legal Events

Date Code Title Description
FG Grant of patent